GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Salarius Pharmaceuticals Inc (NAS:SLRX) » Definitions » E10

Salarius Pharmaceuticals (Salarius Pharmaceuticals) E10 : $-741.44 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Salarius Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Salarius Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.410. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-741.44 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-06), Salarius Pharmaceuticals's current stock price is $0.43. Salarius Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $-741.44. Salarius Pharmaceuticals's Shiller PE Ratio of today is .


Salarius Pharmaceuticals E10 Historical Data

The historical data trend for Salarius Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Salarius Pharmaceuticals E10 Chart

Salarius Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Salarius Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -741.44

Competitive Comparison of Salarius Pharmaceuticals's E10

For the Biotechnology subindustry, Salarius Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Salarius Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Salarius Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Salarius Pharmaceuticals's Shiller PE Ratio falls into.



Salarius Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Salarius Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.41/131.7762*131.7762
=-0.410

Current CPI (Mar. 2024) = 131.7762.

Salarius Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -242.218 100.560 -317.410
201409 -219.739 100.428 -288.330
201412 0.000 99.070 0.000
201503 -368.750 99.621 -487.773
201506 -293.750 100.684 -384.463
201509 -331.250 100.392 -434.806
201512 -318.750 99.792 -420.910
201603 -381.250 100.470 -500.045
201606 -443.750 101.688 -575.049
201609 -406.250 101.861 -525.560
201612 -300.000 101.863 -388.099
201703 -306.250 102.862 -392.335
201706 -318.750 103.349 -406.425
201709 -337.500 104.136 -427.082
201712 -287.500 104.011 -364.246
201803 -287.500 105.290 -359.824
201806 -312.500 106.317 -387.334
201809 -93.750 106.507 -115.993
201812 -68.750 105.998 -85.470
201903 -75.000 107.251 -92.151
201906 -7.500 108.070 -9.145
201909 -18.250 108.329 -22.200
201912 -11.000 108.420 -13.370
202003 -5.500 108.902 -6.655
202006 -3.250 108.767 -3.938
202009 -2.500 109.815 -3.000
202012 -2.500 109.897 -2.998
202103 -1.500 111.754 -1.769
202106 -1.750 114.631 -2.012
202109 -2.090 115.734 -2.380
202112 -2.250 117.630 -2.521
202203 -3.300 121.301 -3.585
202206 -2.200 125.017 -2.319
202209 -6.410 125.227 -6.745
202212 -2.750 125.222 -2.894
202303 -2.230 127.348 -2.308
202306 -1.430 128.729 -1.464
202309 -0.650 129.860 -0.660
202312 0.000 129.419 0.000
202403 -0.410 131.776 -0.410

Add all the adjusted EPS together and divide 10 will get our e10.


Salarius Pharmaceuticals  (NAS:SLRX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Salarius Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Salarius Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Salarius Pharmaceuticals (Salarius Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The Company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Executives
Tess Burleson director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan I Lieber director C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
William K. Mcvicar director C/O INOTEK PHARMACEUTICALS CORPORATION, 131 HARTWELL AVENUE, SUITE 105, LEXINGTON MA 02421
Arnold C Hanish director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Mark J Rosenblum officer: Exec VP Finance, Interim CFO 3990 SPRING VALLEY ROAD, APT. 1218, DALLAS TX 75244
David J. Arthur director, officer: Chief Executive Officer 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Scott Jordan officer: Chief Financial Officer 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Mccreedy Bruce J Jr. director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan P Northrup director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Pao-yu Chuang officer: Controller 2450 HOLCOMBE BLVD., SUITE J-608, HOUSTON TX 77021
Paul Lammers director 2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Boston Foundation, Inc. 10 percent owner 75 ARLINGTON STREET, BOSTON MA 02116
Christoph H Westphal 10 percent owner C/O ALNYLAM PHARMACEUTICALS, INC, 300 THIRD STREET, CAMBRIDGE MA 02142
Longwood Fund Ii, L.p. 10 percent owner 800 BOYLSTON STREET, SUITE 1555, BOSTON MA 02199
Roger D Tung director 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421

Salarius Pharmaceuticals (Salarius Pharmaceuticals) Headlines

From GuruFocus